Intranasal delivery of nanoparticle-based vaccines.
Most pathogens gain access to the human body and initiate systemic infections through mucosal sites. A large number of currently marketed licensed vaccines are parenterally administered; they generate strong systemic immunity but not mucosal immunity. Nasal vaccination is an appealing strategy for the induction of mucosal-specific immunity; however, its development is mostly challenged by several factors, such as inefficient antigen uptake, its rapid mucociliary clearance, size-restricted permeation across epithelial barriers and absence of safe human mucosal adjuvants. Therefore, a safer mucosal-adjuvanting strategy or efficient mucosal delivery platform is much warranted. This review summarizes challenges and the rationale for nasal vaccine development with a special focus on the use of nanoparticles based on polymers and lipids for mucosal vaccine delivery.
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia.|School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, 4072, Australia.
Nirmal
N
Marasini
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia.
Mariusz
M
Skwarczynski
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia.|Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia.|School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Istvan
I
Toth
D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D006801:Humans; D018928:Immunity, Mucosal; D053758:Nanoparticles; D014611:Vaccination / Q000379:methods*; D014612:Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D014612:Vaccines
lipids; mucosal immunity; nanoparticles; nasal vaccines; polymers